LakeShore Biopharma Files 2024 Annual Report

Ticker: LSBWF · Form: 20-F · Filed: Aug 15, 2024 · CIK: 1946399

Lakeshore Biopharma CO., LTD. 20-F Filing Summary
FieldDetail
CompanyLakeshore Biopharma CO., LTD. (LSBWF)
Form Type20-F
Filed DateAug 15, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.00002, $1, $45,099,071 b, $1,008,768 b
Sentimentneutral

Sentiment: neutral

Topics: annual-report, 20-f, biopharma

TL;DR

LakeShore Biopharma (fka YS Biopharma) filed its 2024 20-F. All good.

AI Summary

LakeShore Biopharma Co., Ltd. filed its annual report on Form 20-F for the fiscal year ended March 31, 2024. The company, formerly known as YS Biopharma Co., Ltd. and YishengBio Co., Ltd., is based in Beijing, China, and operates in the pharmaceutical preparations industry. The filing confirms its status as an annual report under the Securities Exchange Act of 1934.

Why It Matters

This filing provides investors with an updated overview of LakeShore Biopharma's financial health and operational status for the fiscal year ending March 31, 2024.

Risk Assessment

Risk Level: medium — As a foreign private issuer filing a 20-F, the company is subject to different reporting and regulatory standards compared to domestic US companies, which can introduce additional complexities for investors.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of LakeShore Biopharma Co., Ltd.?

LakeShore Biopharma Co., Ltd. operates in the Pharmaceutical Preparations industry, as indicated by its Standard Industrial Classification code [2834].

When did the company change its name from YS Biopharma Co., Ltd.?

The company's name was changed from YS Biopharma Co., Ltd. on March 10, 2023.

What is the filing date of this 20-F report?

This 20-F report was filed on August 15, 2024.

Where is LakeShore Biopharma Co., Ltd. located?

The company's business and mailing address is Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, China, with a ZIP code of 102629.

What is the SEC file number for this filing?

The SEC file number for this filing is 001-41598.

Filing Stats: 4,526 words · 18 min read · ~15 pages · Grade level 14.3 · Accepted 2024-08-15 07:28:44

Key Financial Figures

Filing Documents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS iv EXPLANATORY NOTE vi PART I 1 ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 1 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 1 ITEM 3. KEY INFORMATION 1 ITEM 4. INFORMATION ON THE COMPANY 77 ITEM 4A. UNRESOLVED STAFF COMMENTS 147 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 147 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 172 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 181 ITEM 8. FINANCIAL INFORMATION 182 ITEM 9. THE OFFER AND LISTING 182 ITEM 10. ADDITIONAL INFORMATION 183 ITEM 11.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 199 ITEM 12.

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 199 PART II 200 ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES 200 ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS 200 ITEM 15.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 200 ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT 201 ITEM 16B. CODE OF ETHICS 201 ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES 202 ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES 202 ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS 202 ITEM 16F. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT 202 ITEM 16G. CORPORATE GOVERNANCE 202 ITEM 16H. MINE SAFETY DISCLOSURE 203 ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 203 ITEM 16J. INSIDER TRADING POLICIES 203 ITEM 16K. CYBERSECURITY 203 PART III 205 ITEM 17.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 205 ITEM 18.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 205 ITEM 19. EXHIBITS 205

SIGNATURES

SIGNATURES 206 i INTRODUCTION Unless otherwise indicated or the context otherwise requires in this annual report on Form 20-F (this "Annual Report"): "Articles" or "Articles of Association" means our amended and restated memorandum and articles (as amended and restated from time to time), adopted on September 23, 2022 and effective on March 16, 2023; "Beijing Yisheng" means Beijing Yisheng Biotechnology Co., Ltd., a company incorporated under the laws of the PRC with limited liability and our wholly-owned subsidiary; "Board" means our board of directors; "Business Combination" means the transactions contemplated by the Business Combination Agreement which was consummated on March 16, 2023; "Business Combination Agreement" means the business combination agreement, dated as of September 29, 2022, by and among LakeShore Biopharma, SPAC, Merger Sub I and Merger Sub II; "Cayman Companies Act" means the Companies Act (as Revised) of the Cayman Islands; "CDC(s)" means the Center(s) for Disease Control and Prevention; "China" or "PRC" means the People's Republic of China (and, only in the context of describing the industry matters, and the PRC laws, rules, regulations, regulatory authorities, and any PRC entities or citizens under such rules, laws and regulations and other legal, regulatory or tax matters and advice in this Annual Report, excludes Hong Kong, Macau and Taiwan). The term "Chinese" has a correlative meaning for the purpose of this Annual Report; "Code" means the Internal Revenue Code of the 1986, as amended; "Company," "LakeShore Biopharma," "we," "our," "us," or similar terms means LakeShore Biopharma Co., Ltd (formerly known as YS Biopharma Co., Ltd.), a company incorporated in the Cayman Islands with limited liability and, where the context requires, its consolidated subsidiaries from time to time; "Exchange Act" means the U.S. Securities Exchange Act of 1934, as amended; "GMP" means Good Manufacturing Practices; "HK LakeShore

View Full Filing

View this 20-F filing on SEC EDGAR

View on Read The Filing